Building Your Care Team: The Specialized Approach
At a Glance
Treating pleural mesothelioma requires a specialized multidisciplinary tumor board at a high-volume cancer center. Your core team should include a thoracic pathologist, thoracic surgeon, medical oncologist, and radiation oncologist to ensure an accurate diagnosis and effective treatment plan.
Because pleural mesothelioma is a rare and aggressive disease, the quality of your care depends almost entirely on the expertise of the people treating you [1]. Research shows that patients who receive treatment at high-volume centers—hospitals that specialize in mesothelioma—often have better survival outcomes and fewer complications than those treated at local community hospitals [2].
The Power of the Multidisciplinary Tumor Board
The “gold standard” for mesothelioma care is a Multidisciplinary Tumor Board (MDTB) [2]. This is not just a single doctor, but a formal meeting where a group of specialists sit down together to review your specific scans, pathology, and health history to build a unified plan [3].
Instead of one doctor guessing the best path forward, you benefit from the collective wisdom of several experts at once [2]. Current guidelines from major cancer organizations state that this coordinated approach is absolutely essential for a disease as complex as mesothelioma [2][3].
Key Members of Your Care Team
A specialized team should include at least these four core experts:
- Thoracic Pathologist: Mesothelioma is notoriously difficult to diagnose. A pathologist who specializes in chest cancers is critical for ensuring your diagnosis (and subtype) is 100% accurate, often using specialized tests like BAP1 and MTAP [1][4].
- Thoracic Surgeon: This is a surgeon who specializes in the chest cavity. In a high-volume center, they perform complex, lung-sparing procedures (like Pleurectomy/Decortication) frequently, which is linked to better safety [5].
- Medical Oncologist: This doctor manages systemic treatments like chemotherapy and immunotherapy [3]. They stay up-to-date on the latest trial results (like CheckMate 743) and know how to manage the side effects of these drugs [6].
- Radiation Oncologist: If radiation is part of your plan, you need an expert who knows how to target the pleura (lung lining) while protecting the sensitive lung and heart tissue nearby [7].
The Timeline: What to Expect
For a newly diagnosed patient, waiting for answers can be agonizing. Knowing the typical timeline can help set expectations:
- Biopsy and Pathology: Once a tissue sample is taken, specialized immunohistochemistry (IHC) staining takes time. It can take 1 to 2 weeks for a full pathology report to be finalized [1].
- Tumor Board Review: After the pathology is confirmed and all PET/CT scans are completed, the multidisciplinary tumor board meets to review the case [2]. This can take an additional week.
While the wait is difficult, getting the diagnosis exactly right before starting treatment is crucial for your long-term success.
If your current hospital does not have a formal mesothelioma multidisciplinary team, you have the right to request a second opinion at an NCI-designated or high-volume cancer center [2].
Common questions in this guide
Why is it important to go to a high-volume center for pleural mesothelioma?
What is a multidisciplinary tumor board?
Who should be on my mesothelioma care team?
How long does it take to get a mesothelioma treatment plan?
Should I get a second opinion for pleural mesothelioma?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many mesothelioma-specific cases does this hospital and this surgical team treat each year?
- 2.Will my case be reviewed by a formal multidisciplinary tumor board that includes a thoracic-specialized pathologist?
- 3.Who is the 'lead' coordinator for my care team—is there a nurse navigator who will help me manage appointments?
- 4.What experience does your radiation oncology team have in treating mesothelioma, specifically using modern techniques to protect the remaining lung?
- 5.Does this center offer clinical trials specifically for mesothelioma that aren't available at my local hospital?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (7)
- 1
Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.
Lucà S, Pignata G, Cioce A, et al.
Cancers 2025; (17(3)) doi:10.3390/cancers17030481.
PMID: 39941848 - 2
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Kindler HL, Ismaila N, Bazhenova L, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(8)):1006-1038 doi:10.1200/JCO-24-02425.
PMID: 39778125 - 3
Malignant pleural mesothelioma: The disdained member of thoracic oncology!
Khosla D, Singh PK, Chhabria BA, et al.
World journal of experimental medicine 2024; (14(3)):91739 doi:10.5493/wjem.v14.i3.91739.
PMID: 39312698 - 4
Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R, Castañeda-González JP, Chaves-Cabezas V, et al.
Pathology, research and practice 2024; (257()):155276 doi:10.1016/j.prp.2024.155276.
PMID: 38603842 - 5
Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma.
van Gerwen M, Wolf A, Liu B, et al.
Journal of surgical oncology 2018; (118(7)):1178-1187 doi:10.1002/jso.25260.
PMID: 30293239 - 6
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
Scherpereel A, Baas P, Nowak AK, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; (44(9)):742-749 doi:10.1200/JCO-25-01328.
PMID: 41734361 - 7
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Kindler HL, Ismaila N, Armato SG, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1343-1373 doi:10.1200/JCO.2017.76.6394.
PMID: 29346042
This page is for informational purposes only and does not replace professional medical advice. Always consult a mesothelioma specialist about your specific care team and treatment plan.
Get notified when new evidence is published on Pleural mesothelioma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.